You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍跑贏 金斯瑞(01548.HK)午後升逾10% 惟3D MEDICINES(01244.HK)續挫13%至半年低
恆指繼今早(21日)曾回升241點至19,169(受制50天線),午後升幅繼續收窄,現報19,002,僅回升74點或0.4%,總成交額557億元。 美股強生(JNJ.US)季績勝預期兼調高全年盈測,刺激股價隔晚(20日)漲逾6%,季績勝預期雅培(ABT.US)股價續升逾4%.,默沙東(MRK.US)也升2.4%。 本港醫藥板塊今天普遍跑贏,尤其是披露次季CARVYKTI產生貿易銷售淨額的金斯瑞(01548.HK)午後升幅擴大,股價曾升破50天線(18.25元),最多急漲近12%高見18.34元,現報18.16元,急漲10.5%,成交急增至2,452萬股。 藍籌醫藥股石藥(01093.HK)、中生製藥(01177.HK)、藥明生物(02269.HK)及翰森製藥(03692.HK)現微升0.5%至0.9%。藍籌線上醫療股阿里健康(00241.HK)、京東健康(06618.HK)及非藍籌平安好醫生(01833.HK)亦升0.8%至1.8%。 先聲藥業(02096.HK)、泰格醫藥(03347.HK)、康希諾(06185.HK)、君實生物(01877.HK)、信達生物(01801.HK)、雲頂新耀-B(01952.HK)及康方生物-B(09926.HK)升近2.5%至5%;當中以康方生物升幅最大,股價重越10天、20天及50天線,午後高見37.8元。 然而,連續兩天股價累瀉五成的3D MEDICINES(01244.HK)發表不悉股價及成交不尋常波動聲明。該股今天高開2.1%報61.5元欠承接,掉頭曾挫17%低見49.95元創半年低,現報52.4元,續挫13%。 歌禮制藥-B(01672.HK)昨天公佈天治療原發性膽汁性膽管炎藥物臨牀試驗完成患者入組,股價連升兩天後,今天回吐4.9%報2.15元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account